Published in Biochim Biophys Acta on November 05, 2004
Synergistic interactions between repeats in tau protein and Aβ amyloids may be responsible for accelerated aggregation via polymorphic states. Biochemistry (2011) 1.03
Clinical proteomics and OMICS clues useful in translational medicine research. Proteome Sci (2012) 0.83
Technical phosphoproteomic and bioinformatic tools useful in cancer research. J Clin Bioinforma (2011) 0.83
Discovering and validating unknown phospho-sites from p38 and HuR protein kinases in vitro by Phosphoproteomic and Bioinformatic tools. J Clin Bioinforma (2011) 0.81
Compartmental protein expression of Tau, GSK-3beta and TrkA in cholinergic neurons of aged rats. J Neural Transm (Vienna) (2006) 0.75
Atom-by-atom analysis of global downhill protein folding. Nature (2006) 4.50
Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem (2003) 2.65
First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem (2002) 2.45
Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem (2007) 2.44
Experimental identification of downhill protein folding. Science (2002) 2.43
Inhibition of glycogen synthase kinase 3beta during heart failure is protective. Circ Res (2007) 2.22
How fast is protein hydrophobic collapse? Proc Natl Acad Sci U S A (2003) 2.01
Non-ATP competitive glycogen synthase kinase 3beta (GSK-3beta) inhibitors: study of structural requirements for thiadiazolidinone derivatives. Bioorg Med Chem (2007) 1.98
Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem (2004) 1.97
Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res (2006) 1.94
Neuronal induction of the immunoproteasome in Huntington's disease. J Neurosci (2003) 1.83
Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev (2003) 1.59
Dynamics of one-state downhill protein folding. Proc Natl Acad Sci U S A (2008) 1.52
Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci (2007) 1.50
Extracellular tau is toxic to neuronal cells. FEBS Lett (2006) 1.47
Scaling of folding times with protein size. J Am Chem Soc (2005) 1.46
A photoprotection strategy for microsecond-resolution single-molecule fluorescence spectroscopy. Nat Methods (2011) 1.46
Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci (2006) 1.44
Arginase I induction in macrophages, triggered by Th2-type cytokines, supports the growth of intracellular Leishmania parasites. Parasite Immunol (2002) 1.44
Biomagnification study on organochlorine compounds in marine aquaculture: the sea bass (Dicentrarchus labrax) as a model. Environ Sci Technol (2003) 1.44
Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr (2007) 1.43
Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem (2002) 1.42
Exploring one-state downhill protein folding in single molecules. Proc Natl Acad Sci U S A (2011) 1.42
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. AIDS (2004) 1.37
Estimating free-energy barrier heights for an ultrafast folding protein from calorimetric and kinetic data. J Phys Chem B (2008) 1.34
Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? Free Radic Biol Med (2002) 1.34
Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem (2006) 1.34
Distinct priming kinases contribute to differential regulation of collapsin response mediator proteins by glycogen synthase kinase-3 in vivo. J Biol Chem (2006) 1.33
GSK3: a possible link between beta amyloid peptide and tau protein. Exp Neurol (2009) 1.32
Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis (2003) 1.29
Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease. J Alzheimers Dis (2009) 1.29
Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity. Mol Biol Cell (2006) 1.29
Protein folding kinetics: barrier effects in chemical and thermal denaturation experiments. J Am Chem Soc (2007) 1.29
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations. J Virol (2005) 1.24
The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med Res Rev (2009) 1.22
Insights into protein folding mechanisms from large scale analysis of mutational effects. Proc Natl Acad Sci U S A (2010) 1.21
Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J Virol (2006) 1.21
Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimer's disease. J Biol Chem (2003) 1.19
Robustness of downhill folding: guidelines for the analysis of equilibrium folding experiments on small proteins. Biochemistry (2005) 1.18
Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. FEBS Lett (2011) 1.17
A simple thermodynamic test to discriminate between two-state and downhill folding. J Am Chem Soc (2004) 1.16
Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Neurobiol Dis (2005) 1.16
N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. J Biol Chem (2007) 1.15
Tissue-nonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau. J Biol Chem (2010) 1.15
The nature of the free energy barriers to two-state folding. Proteins (2004) 1.14
Development of a new family of conformationally restricted peptides as potent nucleators of beta-turns. Design, synthesis, structure, and biological evaluation of a beta-lactam peptide analogue of melanostatin. J Am Chem Soc (2003) 1.13
A role of MAP1B in Reelin-dependent neuronal migration. Cereb Cortex (2004) 1.13
Dynamics, energetics, and structure in protein folding. Biochemistry (2006) 1.13
Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiol Dis (2005) 1.11
SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors. J Med Chem (2005) 1.11
Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase 3. Biochem J (2003) 1.11
Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation. J Neurosci (2010) 1.10
Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications. Prog Biophys Mol Biol (2005) 1.08
Regulation of GSK3 isoforms by phosphatases PP1 and PP2A. Mol Cell Biochem (2010) 1.08
Comparing illicit drug use in 19 European cities through sewage analysis. Sci Total Environ (2012) 1.07
Molecular determinants of topoisomerase I poisoning by lamellarins: comparison with camptothecin and structure-activity relationships. J Med Chem (2005) 1.06
Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits. Neurobiol Dis (2009) 1.06
Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines. Biochem Pharmacol (2009) 1.06
Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol Aging (2005) 1.05
Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease. Int J Exp Pathol (2008) 1.04
Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain. J Neurosci (2004) 1.04
Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. EMBO J (2007) 1.04
Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. Curr Pharm Des (2010) 1.04
GSK-3 inhibitors for Alzheimer's disease. Expert Rev Neurother (2007) 1.04
MAP1B is required for Netrin 1 signaling in neuronal migration and axonal guidance. Curr Biol (2004) 1.04
A new mutation of the tau gene, G303V, in early-onset familial progressive supranuclear palsy. Arch Neurol (2005) 1.04
Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice. Microbes Infect (2008) 1.03
Glycogen synthase kinase-3 is activated in neuronal cells by Galpha12 and Galpha13 by Rho-independent and Rho-dependent mechanisms. J Neurosci (2002) 1.03
Expanding the realm of ultrafast protein folding: gpW, a midsize natural single-domain with alpha+beta topology that folds downhill. J Am Chem Soc (2008) 1.03
Leishmania infantum expresses a mitochondrial nuclease homologous to EndoG that migrates to the nucleus in response to an apoptotic stimulus. Mol Biochem Parasitol (2008) 1.03
Multi-class determination of around 50 pharmaceuticals, including 26 antibiotics, in environmental and wastewater samples by ultra-high performance liquid chromatography-tandem mass spectrometry. J Chromatogr A (2011) 1.02
Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis. Vaccine (2004) 1.02
Programmed cell death in trypanosomatids: a way to maximize their biological fitness? Trends Parasitol (2004) 1.02
Creating a transatlantic research enterprise for preventing Alzheimer's disease. Alzheimers Dement (2009) 1.02
Chronological primacy of oxidative stress in Alzheimer disease. Neurobiol Aging (2005) 1.02
ET-18-OCH3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor. Curr Med Chem (2004) 1.01
The role of GSK3 in Alzheimer disease. Brain Res Bull (2009) 1.00
Integrated prediction of protein folding and unfolding rates from only size and structural class. Phys Chem Chem Phys (2011) 1.00
MAP1B regulates microtubule dynamics by sequestering EB1/3 in the cytosol of developing neuronal cells. EMBO J (2013) 1.00
Deconstructing mitochondrial dysfunction in Alzheimer disease. Oxid Med Cell Longev (2013) 0.99
Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: a single mode of inhibition for the three HIV enzymes? Antiviral Res (2006) 0.99
GSK3β overexpression induces neuronal death and a depletion of the neurogenic niches in the dentate gyrus. Hippocampus (2010) 0.99
The influence of phospho-τ on dendritic spines of cortical pyramidal neurons in patients with Alzheimer's disease. Brain (2013) 0.99
Estradiol prevents neural tau hyperphosphorylation characteristic of Alzheimer's disease. Ann N Y Acad Sci (2005) 0.99
Molecular mechanisms for the B-Z transition in the example of poly[d(G-C) x d(G-C)] polymers. A critical review. Chem Rev (2006) 0.98